What type of cancer is Platinib mainly used to treat?

Pralsetinib (Pralsetinib) is a tyrosine kinase inhibitor (TKI). It inhibits the RET receptor tyrosine kinase activity on tumor cells and blocks the signal transduction pathway, thereby inhibiting the growth and spread of tumor cells and having high selectivity for tumor cells. Platinib can be used to treat non-small cell lung cancer (NSCLC) and thyroid cancer that carry activating mutations in the RET gene. For patients with NSCLC, if a fusion RET gene mutation is detected, platinib can be used as a first-line or second-line treatment. For patients with thyroid cancer, platinib can be used as an optional treatment.